Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Biol Chem
2009 May 08;28419:12862-73. doi: 10.1074/jbc.M805123200.
Show Gene links
Show Anatomy links
The serine protease plasmin cleaves the amino-terminal domain of the NR2A subunit to relieve zinc inhibition of the N-methyl-D-aspartate receptors.
Yuan H
,
Vance KM
,
Junge CE
,
Geballe MT
,
Snyder JP
,
Hepler JR
,
Yepes M
,
Low CM
,
Traynelis SF
.
???displayArticle.abstract???
Zinc is hypothesized to be co-released with glutamate at synapses of the central nervous system. Zinc binds to NR1/NR2A N-methyl-d-aspartate (NMDA) receptors with high affinity and inhibits NMDAR function in a voltage-independent manner. The serine protease plasmin can cleave a number of substrates, including protease-activated receptors, and may play an important role in several disorders of the central nervous system, including ischemia and spinal cord injury. Here, we demonstrate that plasmin can cleave the native NR2A amino-terminal domain (NR2A(ATD)), removing the functional high affinity Zn(2+) binding site. Plasmin also cleaves recombinant NR2A(ATD) at lysine 317 (Lys(317)), thereby producing a approximately 40-kDa fragment, consistent with plasmin-induced NR2Acleavage fragments observed in rat brain membrane preparations. A homology model of the NR2A(ATD) predicts that Lys(317) is near the surface of the protein and is accessible to plasmin. Recombinant expression of NR2A with an amino-terminal deletion at Lys(317) is functional and Zn(2+) insensitive. Whole cell voltage-clamp recordings show that Zn(2+) inhibition of agonist-evoked NMDA receptor currents of NR1/NR2A-transfected HEK 293 cells and cultured cortical neurons is significantly reduced by plasmin treatment. Mutating the plasmincleavage site Lys(317) on NR2A to alanine blocks the effect of plasmin on Zn(2+) inhibition. The relief of Zn(2+) inhibition by plasmin occurs in PAR1(-/-) cortical neurons and thus is independent of interaction with protease-activated receptors. These results suggest that plasmin can directly interact with NMDA receptors, and plasmin may increase NMDA receptor responses through disruption or removal of the amino-terminal domain and relief of Zn(2+) inhibition.
Aizenman,
Induction of neuronal apoptosis by thiol oxidation: putative role of intracellular zinc release.
2000, Pubmed
Aizenman,
Induction of neuronal apoptosis by thiol oxidation: putative role of intracellular zinc release.
2000,
Pubmed
Benchenane,
Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis.
2005,
Pubmed
Bi,
Calpain-mediated regulation of NMDA receptor structure and function.
1998,
Pubmed
Biswas,
Proteolytic cleavage of human chromogranin a containing naturally occurring catestatin variants: differential processing at catestatin region by plasmin.
2008,
Pubmed
Bokesch,
NMDA receptor antibodies predict adverse neurological outcome after cardiac surgery in high-risk patients.
2006,
Pubmed
Carmeliet,
Molecular genetics of the fibrinolytic and coagulation systems in haemostasis, thrombogenesis, restenosis and atherosclerosis.
1997,
Pubmed
Chain,
Plasmin cleavage of vitronectin. Identification of the site and consequent attenuation in binding plasminogen activator inhibitor-1.
1991,
Pubmed
Chen,
Differential sensitivity of recombinant N-methyl-D-aspartate receptor subtypes to zinc inhibition.
1997,
Pubmed
Choi,
Zinc and brain injury.
1998,
Pubmed
Choi,
Identification and mechanism of action of two histidine residues underlying high-affinity Zn2+ inhibition of the NMDA receptor.
1999,
Pubmed
,
Xenbase
Christine,
Effect of zinc on NMDA receptor-mediated channel currents in cortical neurons.
1990,
Pubmed
Cuajungco,
Zinc metabolism in the brain: relevance to human neurodegenerative disorders.
1997,
Pubmed
Dambinova,
Multiple panel of biomarkers for TIA/stroke evaluation.
2002,
Pubmed
Dambinova,
Blood test detecting autoantibodies to N-methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke.
2003,
Pubmed
Dingledine,
The glutamate receptor ion channels.
1999,
Pubmed
Erreger,
Zinc inhibition of rat NR1/NR2A N-methyl-D-aspartate receptors.
2008,
Pubmed
Erreger,
Glutamate receptor gating.
2004,
Pubmed
Erreger,
Allosteric interaction between zinc and glutamate binding domains on NR2A causes desensitization of NMDA receptors.
2005,
Pubmed
Fayyazuddin,
Four residues of the extracellular N-terminal domain of the NR2A subunit control high-affinity Zn2+ binding to NMDA receptors.
2000,
Pubmed
,
Xenbase
Fernández-Monreal,
Arginine 260 of the amino-terminal domain of NR1 subunit is critical for tissue-type plasminogen activator-mediated enhancement of N-methyl-D-aspartate receptor signaling.
2004,
Pubmed
Frederickson,
The neurobiology of zinc in health and disease.
2005,
Pubmed
Gingrich,
Potentiation of NMDA receptor function by the serine protease thrombin.
2000,
Pubmed
Gingrich,
Serine proteases and brain damage - is there a link?
2000,
Pubmed
Gray,
Activation of pro-BDNF by the pericellular serine protease plasmin.
2008,
Pubmed
Guttmann,
Specific proteolysis of the NR2 subunit at multiple sites by calpain.
2001,
Pubmed
Guttmann,
Proteolysis of the N-methyl-d-aspartate receptor by calpain in situ.
2002,
Pubmed
Hatton,
Modulation of triheteromeric NMDA receptors by N-terminal domain ligands.
2005,
Pubmed
,
Xenbase
Hewick,
A gas-liquid solid phase peptide and protein sequenator.
1981,
Pubmed
Junge,
The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia.
2003,
Pubmed
Kemp,
NMDA receptor pathways as drug targets.
2002,
Pubmed
Kidwell,
Thrombolytic toxicity: blood brain barrier disruption in human ischemic stroke.
2008,
Pubmed
Kuliopulos,
Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy.
1999,
Pubmed
Kunishima,
Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor.
2000,
Pubmed
Lee,
Astrocytic control of synaptic NMDA receptors.
2007,
Pubmed
Legendre,
The inhibition of single N-methyl-D-aspartate-activated channels by zinc ions on cultured rat neurones.
1990,
Pubmed
Liotta,
Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane.
1981,
Pubmed
Loew,
Proteolysis of the exodomain of recombinant protease-activated receptors: prediction of receptor activation or inactivation by MALDI mass spectrometry.
2000,
Pubmed
Low,
Molecular determinants of coordinated proton and zinc inhibition of N-methyl-D-aspartate NR1/NR2A receptors.
2000,
Pubmed
,
Xenbase
Malherbe,
Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor.
2003,
Pubmed
Mannaioni,
Plasmin potentiates synaptic N-methyl-D-aspartate receptor function in hippocampal neurons through activation of protease-activated receptor-1.
2008,
Pubmed
Matys,
Tissue plasminogen activator promotes the effects of corticotropin-releasing factor on the amygdala and anxiety-like behavior.
2004,
Pubmed
Mayer,
The action of zinc on synaptic transmission and neuronal excitability in cultures of mouse hippocampus.
1989,
Pubmed
Mizutani,
Possible involvement of plasmin in long-term potentiation of rat hippocampal slices.
1996,
Pubmed
Nagai,
Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice.
1999,
Pubmed
Nagai,
The tissue plasminogen activator-plasmin system participates in the rewarding effect of morphine by regulating dopamine release.
2004,
Pubmed
Nicole,
The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling.
2001,
Pubmed
Novak,
Plasmin-mediated proteolysis of osteocalcin.
1997,
Pubmed
Pang,
Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity.
2004,
Pubmed
Paoletti,
NMDA receptor subunits: function and pharmacology.
2007,
Pubmed
Paoletti,
Molecular organization of a zinc binding n-terminal modulatory domain in a NMDA receptor subunit.
2000,
Pubmed
,
Xenbase
Paoletti,
High-affinity zinc inhibition of NMDA NR1-NR2A receptors.
1997,
Pubmed
,
Xenbase
Pawlak,
Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors.
2005,
Pubmed
Perin-Dureau,
Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors.
2002,
Pubmed
,
Xenbase
Pryzdial,
Plasmin converts factor X from coagulation zymogen to fibrinolysis cofactor.
1999,
Pubmed
Qureshi,
Tissue plasminogen activator for acute ischemic stroke.
1996,
Pubmed
Rachline,
The micromolar zinc-binding domain on the NMDA receptor subunit NR2B.
2005,
Pubmed
,
Xenbase
Samson,
Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function.
2008,
Pubmed
,
Xenbase
Schmidlin,
Protease-activated receptors: how proteases signal to cells.
2001,
Pubmed
Sheehan,
Fibrin-modifying serine proteases thrombin, tPA, and plasmin in ischemic stroke: a review.
2005,
Pubmed
Southan,
Characterization of peptides cleaved by plasmin from the C-terminal polymerization domain of human fibrinogen.
1985,
Pubmed
Stys,
White matter NMDA receptors: an unexpected new therapeutic target?
2007,
Pubmed
Takagi,
Amino acid sequence studies on the alpha chain of human fibrinogen. Location of four plasmin attack points and a covalent cross-linking site.
1975,
Pubmed
Tomimatsu,
Proteases involved in long-term potentiation.
2002,
Pubmed
Traynelis,
Control of voltage-independent zinc inhibition of NMDA receptors by the NR1 subunit.
1998,
Pubmed
,
Xenbase
Traynelis,
Protease-activated receptor signaling: new roles and regulatory mechanisms.
2007,
Pubmed
Tsirka,
Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator.
1995,
Pubmed
Tsirka,
Clinical implications of the involvement of tPA in neuronal cell death.
1997,
Pubmed
Vallee,
The biochemical basis of zinc physiology.
1993,
Pubmed
Vogt,
The actions of synaptically released zinc at hippocampal mossy fiber synapses.
2000,
Pubmed
Wang,
Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice.
1998,
Pubmed
Westbrook,
Micromolar concentrations of Zn2+ antagonize NMDA and GABA responses of hippocampal neurons.
,
Pubmed
Williams,
Ifenprodil, a novel NMDA receptor antagonist: site and mechanism of action.
2001,
Pubmed
Williams,
Separating dual effects of zinc at recombinant N-methyl-D-aspartate receptors.
1996,
Pubmed
,
Xenbase
Wong,
Expression and characterization of soluble amino-terminal domain of NR2B subunit of N-methyl-D-aspartate receptor.
2005,
Pubmed
Woodburn,
Neuroprotective actions of excitatory amino acid receptor antagonists.
1994,
Pubmed
Xie,
A physiological role for endogenous zinc in rat hippocampal synaptic neurotransmission.
1991,
Pubmed
Xue,
Acute tissue damage after injections of thrombin and plasmin into rat striatum.
2001,
Pubmed
